Biopharma Venture Capital In Europe: Still Alive, And Starting To Wake Up
By
Melanie Senior / Email the Author / START-UP April 2011, Vol. 16, No. 4
Venture Round / Word Count: 2550 / Article # 2011900083
Executive Summary
European VC is enjoying a revival -- of sorts. It was badly hit by the financial crisis, but now attractively low valuations, plus a continuing stream of opportunities, including Big Pharma spin-outs, are starting to lure some investors back, and provide validation for stalwarts who remained committed during the lean times.
$125.00
Buy Now
For $125.00, purchase this 2550-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.